-
1
-
-
84960796740
-
Cancer statistics inChina, 2015
-
W. Chen, R. Zheng, P. D. Baade et al., "Cancer statistics inChina, 2015, " CA: Cancer Journal for Clinicians, vol. 66, no. 2, pp. 115-132, 2016.
-
(2016)
CA: Cancer Journal for Clinicians
, vol.66
, Issue.2
, pp. 115-132
-
-
Chen, W.1
Zheng, R.2
Baade, P.D.3
-
2
-
-
0345872083
-
Multidisciplinary management of lung cancer
-
A. Spira and D. S. Ettinger, "Multidisciplinary management of lung cancer, "The New England Journal ofMedicine, vol. 350, no. 4, pp. 379-392, 2004.
-
(2004)
The New England Journal OfMedicine
, vol.350
, Issue.4
, pp. 379-392
-
-
Spira, A.1
Ettinger, D.S.2
-
3
-
-
2942547465
-
Small cell lung cancer: State of the art and future perspectives
-
R. Stupp, C. Monnerat, A. T. Turrisi, M. C. Perry, andS. Leyvraz, "Small cell lung cancer: state of the art and future perspectives, " Lung Cancer, vol. 45, no. 1, pp. 105-117, 2004.
-
(2004)
Lung Cancer
, vol.45
, Issue.1
, pp. 105-117
-
-
Stupp, R.1
Monnerat, C.2
Turrisi, A.T.3
Perry, M.C.4
Leyvraz, S.5
-
4
-
-
0035742095
-
Current standards of care in small-cell and nonsmall-cell lung cancer
-
J. H. Schiller, "Current standards of care in small-cell and nonsmall-cell lung cancer, " Oncology, vol. 61, no. 1, pp. 3-13, 2001.
-
(2001)
Oncology
, vol.61
, Issue.1
, pp. 3-13
-
-
Schiller, J.H.1
-
5
-
-
0036328377
-
Practice guidelines for tumor marker use in the clinic
-
C. Sturgeon, "Practice guidelines for tumor marker use in the clinic, " Clinical Chemistry, vol. 48, pp. 1151-1159, 2002.
-
(2002)
Clinical Chemistry
, vol.48
, pp. 1151-1159
-
-
Sturgeon, C.1
-
6
-
-
0028330525
-
Pro-gastrin-releasing peptide (31-98) is a specific tumor marker in patients with small cell lung carcinoma
-
Y. Miyake, T. Kodama, and K. Yamaguchi, "Pro-gastrin-releasing peptide (31-98) is a specific tumor marker in patients with small cell lung carcinoma, " Cancer Research, vol. 54, pp. 2136-2140, 1994.
-
(1994)
Cancer Research
, vol.54
, pp. 2136-2140
-
-
Miyake, Y.1
Kodama, T.2
Yamaguchi, K.3
-
7
-
-
0033728154
-
Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treatedwith platinum-based chemotherapy
-
E. Quoix, A. Purohit, M. Faller-Beau, L. Moreau, J. P. Oster, and G. Pauli, "Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treatedwith platinum-based chemotherapy, " LungCancer, vol. 30, no. 2, pp. 127-134, 2000.
-
(2000)
LungCancer
, vol.30
, Issue.2
, pp. 127-134
-
-
Quoix, E.1
Purohit, A.2
Faller-Beau, M.3
Moreau, L.4
Oster, J.P.5
Pauli, G.6
-
8
-
-
0034159916
-
Significance of serumprogastrin-releasing peptide as a predictor of relapse of small cell lung cancer: Comparative evaluation with neuron-specific enolase and carcinoembryonic antigen
-
S. Niho, Y. Nishiwaki, K. Goto et al., "Significance of serumprogastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen, " Lung Cancer, vol. 27, no. 3, pp. 159-167, 2000.
-
(2000)
Lung Cancer
, vol.27
, Issue.3
, pp. 159-167
-
-
Niho, S.1
Nishiwaki, Y.2
Goto, K.3
-
9
-
-
0035103446
-
Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC)
-
T. Shibayama, H. Ueoka, K. Nishii et al., "Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC), " Lung Cancer, vol. 32, no. 1, pp. 61-69, 2001.
-
(2001)
Lung Cancer
, vol.32
, Issue.1
, pp. 61-69
-
-
Shibayama, T.1
Ueoka, H.2
Nishii, K.3
-
10
-
-
0030016693
-
Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): A combined multivariable analysis on data from nine centres
-
L. G. M. Jørgensen, K. Østerlind, J. Genollá et al., "Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres, " British Journal of Cancer, vol. 74, no. 3, pp. 463-467, 1996.
-
(1996)
British Journal of Cancer
, vol.74
, Issue.3
, pp. 463-467
-
-
Jørgensen, L.G.M.1
Østerlind, K.2
Genollá, J.3
-
11
-
-
9344265211
-
Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer
-
M. Díez, A. Torres, M. L. Maestro et al., "Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer, " British Journal of Cancer, vol. 73, no. 10, pp. 1248-1254, 1996.
-
(1996)
British Journal of Cancer
, vol.73
, Issue.10
, pp. 1248-1254
-
-
Díez, M.1
Torres, A.2
Maestro, M.L.3
-
12
-
-
0026937685
-
Prognostic value of pretreatment CEA, SCC-Ag and CA 19-9 levels in sera of patients with non-small cell lung cancer
-
J. Niklinski, M. Furman, J. Laudanski, and M. Kozlowski, "Prognostic value of pretreatment CEA, SCC-Ag and CA 19-9 levels in sera of patients with non-small cell lung cancer, " European Journal of Cancer Prevention, vol. 1, no. 6, pp. 401-406, 1992.
-
(1992)
European Journal of Cancer Prevention
, vol.1
, Issue.6
, pp. 401-406
-
-
Niklinski, J.1
Furman, M.2
Laudanski, J.3
Kozlowski, M.4
-
13
-
-
0033428435
-
Tumor markers CEA, NSE, SCC, TPA and CYFRA 21. 1 in resectable non-small cell lung cancer
-
P. Foa, M. Fornier, and R. Miceli, "Tumor markers CEA, NSE, SCC, TPA and CYFRA 21. 1 in resectable non-small cell lung cancer, " Anticancer Research, vol. 19, pp. 3613-3618, 1999.
-
(1999)
Anticancer Research
, vol.19
, pp. 3613-3618
-
-
Foa, P.1
Fornier, M.2
Miceli, R.3
-
14
-
-
0024935769
-
Preliminary study on CA 125 and CA 19. 9 in primary lung cancer. Relationship with histological subtype of lung carcinoma
-
R. Molina, P. Santabarbara, X. Filella, P. Mengual, and A. M. Ballesta, "Preliminary study on CA 125 and CA 19. 9 in primary lung cancer. Relationship with histological subtype of lung carcinoma, "The International Journal of BiologicalMarkers, vol. 4, pp. 215-220, 1990.
-
(1990)
The International Journal of BiologicalMarkers
, vol.4
, pp. 215-220
-
-
Molina, R.1
Santabarbara, P.2
Filella, X.3
Mengual, P.4
Ballesta, A.M.5
-
15
-
-
0028200489
-
CYFRA 21. 1 in lung cancer: Comparison with CEA, CA 125, SCC and NSE serum levels
-
R. Molina, C. Agusti, M. Mae et al., "CYFRA 21. 1 in lung cancer: comparison with CEA, CA 125, SCC and NSE serum levels, "The International Journal of Biological Markers, vol. 9, pp. 96-101, 1994.
-
(1994)
The International Journal of Biological Markers
, vol.9
, pp. 96-101
-
-
Molina, R.1
Agusti, C.2
Mae, M.3
-
16
-
-
0027293239
-
The new tumor marker CYFRA is superior to SCC antigen and CEA in the primary diagnosis of lung cancer
-
W. Eberth, B. Leichtweis, B. Schapöhler, and T. H. Muley, "The new tumor marker CYFRA is superior to SCC antigen and CEA in the primary diagnosis of lung cancer, " Tumor Diagnostik und Therapie, vol. 14, pp. 91-99, 1993.
-
(1993)
Tumor Diagnostik und Therapie
, vol.14
, pp. 91-99
-
-
Eberth, W.1
Leichtweis, B.2
Schapöhler, B.3
Muley, T.H.4
-
17
-
-
0029557611
-
CYFRA 21. 1 determination in patients with non-small cell lung cancer: Clinical utility for the detection of recurrence
-
J. Niklinski, M. Furman, M. Rappellino et al., "CYFRA 21. 1 determination in patients with non-small cell lung cancer: clinical utility for the detection of recurrence, " The Journal of Cardiovascular Surgery, vol. 36, pp. 501-504, 1995.
-
(1995)
The Journal of Cardiovascular Surgery
, vol.36
, pp. 501-504
-
-
Niklinski, J.1
Furman, M.2
Rappellino, M.3
-
18
-
-
0027279541
-
CYFRA 21-1: A new marker in lung cancer
-
P. Stieber, U. Hasholzner, H. Bodenmüller et al., "CYFRA 21-1: a new marker in lung cancer, " Cancer, vol. 72, no. 3, pp. 707-713, 1993.
-
(1993)
Cancer
, vol.72
, Issue.3
, pp. 707-713
-
-
Stieber, P.1
Hasholzner, U.2
Bodenmüller, H.3
-
19
-
-
0027530418
-
Serumfragment of cytokeratin subunit 19measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer
-
J.-L. Pujol, J. Grenier, J.-P. Daurfes, A. Daver, H. Pujol, and F.-B. Michel, "Serumfragment of cytokeratin subunit 19measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer, " Cancer Research, vol. 53, pp. 61-66, 1993.
-
(1993)
Cancer Research
, vol.53
, pp. 61-66
-
-
Pujol, J.-L.1
Grenier, J.2
Daurfes, J.-P.3
Daver, A.4
Pujol, H.5
Michel, F.-B.6
-
20
-
-
0029073304
-
Cyfra 21-1 as a biologic marker of non-small cell lung cancer: Evaluation of sensitivity, specificity, and prognostic role
-
B. Wieskopf, C. Demangeat, A. Purohit et al., "Cyfra 21-1 as a biologic marker of non-small cell lung cancer: evaluation of sensitivity, specificity, and prognostic role, " Chest, vol. 108, no. 1, pp. 163-169, 1995.
-
(1995)
Chest
, vol.108
, Issue.1
, pp. 163-169
-
-
Wieskopf, B.1
Demangeat, C.2
Purohit, A.3
-
21
-
-
0345059332
-
Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with nonsmall cell lung cancer as an aid in histological diagnosis and prognosis: Comparison with the main clinical and pathological prognostic factors
-
R. Molina, X. Filella, J. M. Augé et al., "Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with nonsmall cell lung cancer as an aid in histological diagnosis and prognosis: comparison with the main clinical and pathological prognostic factors, " Tumor Biology, vol. 24, no. 4, pp. 209-218, 2003.
-
(2003)
Tumor Biology
, vol.24
, Issue.4
, pp. 209-218
-
-
Molina, R.1
Filella, X.2
Augé, J.M.3
-
22
-
-
0041436782
-
-
AACCPress, Washington, DC, USA
-
P. M. Schneider, R. Metzger, J. Barbender, S. Boehm, T. Luebke, and K. Zarghooni, Tumor Markers, Physiology, Pathobiology, Technology and Clinical Applications, AACCPress, Washington, DC, USA, 2002.
-
(2002)
Tumor Markers, Physiology, Pathobiology, Technology and Clinical Applications
-
-
Schneider, P.M.1
Metzger, R.2
Barbender, J.3
Boehm, S.4
Luebke, T.5
Zarghooni, K.6
-
23
-
-
3042685899
-
Tumour associated antigens in the differential diagnosis of lung tumours of unknown origin
-
P. Stieber, H. Dienemann, U. Hasholzner, A. Zimmermann, K. Hofmann, and A. Fateh-Moghadam, "Tumour associated antigens in the differential diagnosis of lung tumours of unknown origin, " Anticancer Research, vol. 15, pp. 2389-2393, 1995.
-
(1995)
Anticancer Research
, vol.15
, pp. 2389-2393
-
-
Stieber, P.1
Dienemann, H.2
Hasholzner, U.3
Zimmermann, A.4
Hofmann, K.5
Fateh-Moghadam, A.6
-
24
-
-
0030960735
-
Analysis of the early postoperative serum carcinoembryonic antigen time-course as a prognostic tool for bronchogenic carcinoma
-
T. Yoshimasu, S. Miyoshi, S. Maebeya et al., "Analysis of the early postoperative serum carcinoembryonic antigen time-course as a prognostic tool for bronchogenic carcinoma, " Cancer, vol. 79, no. 8, pp. 1533-1540, 1997.
-
(1997)
Cancer
, vol.79
, Issue.8
, pp. 1533-1540
-
-
Yoshimasu, T.1
Miyoshi, S.2
Maebeya, S.3
-
25
-
-
84879329196
-
National comprehensive cancer network. Non-small cell lung cancer, version 2. 2013
-
D. S. Ettinger, W. Akerley, H. Borghaei et al. et al., "National comprehensive cancer network. Non-small cell lung cancer, version 2. 2013, " Journal of the National Comprehensive Cancer Network, vol. 11, pp. 645-653, 2013.
-
(2013)
Journal of the National Comprehensive Cancer Network
, vol.11
, pp. 645-653
-
-
Ettinger, D.S.1
Akerley, W.2
Borghaei, H.3
-
26
-
-
84874589027
-
National comprehensive cancer network. Small cell lung cancer
-
G. P. Kalemkerian, W. Akerley, P. Bogner et al. et al., "National comprehensive cancer network. Small cell lung cancer, " Journal of the National Comprehensive Cancer Network, vol. 11, pp. 78-98, 2013.
-
(2013)
Journal of the National Comprehensive Cancer Network
, vol.11
, pp. 78-98
-
-
Kalemkerian, G.P.1
Akerley, W.2
Bogner, P.3
-
27
-
-
15744362912
-
The 2004World Health Organization classification of lung tumors
-
M. B. Beasley, E. Brambilla, and W. D. Travis, "The 2004World Health Organization classification of lung tumors, " Seminars in Roentgenology, vol. 40, no. 2, pp. 90-97, 2005.
-
(2005)
Seminars in Roentgenology
, vol.40
, Issue.2
, pp. 90-97
-
-
Beasley, M.B.1
Brambilla, E.2
Travis, W.D.3
-
28
-
-
66449111135
-
Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: Correlation with histology
-
R. Molina, J. M. Augé, X. Bosch et al., "Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology, " Tumor Biology, vol. 30, no. 3, pp. 121-129, 2009.
-
(2009)
Tumor Biology
, vol.30
, Issue.3
, pp. 121-129
-
-
Molina, R.1
Augé, J.M.2
Bosch, X.3
-
29
-
-
0031924565
-
Tumor markers in response monitoring and prognosis of non-small cell lung cancer: Preliminary report
-
N. Viñolas, R. Molina, M. C. Galán et al., "Tumor markers in response monitoring and prognosis of non-small cell lung cancer: preliminary report, " Anticancer Research, vol. 18, pp. 631-634, 1998.
-
(1998)
Anticancer Research
, vol.18
, pp. 631-634
-
-
Viñolas, N.1
Molina, R.2
Galán, M.C.3
-
30
-
-
0028000030
-
Study of a new tumor marker, CYFRA 21-1, in malignant and nonmalignant diseases
-
R. Molina, C. Agusti, X. Filella et al., "Study of a new tumor marker, CYFRA 21-1, in malignant and nonmalignant diseases, " Tumor Biology, vol. 15, no. 6, pp. 318-325, 1994.
-
(1994)
Tumor Biology
, vol.15
, Issue.6
, pp. 318-325
-
-
Molina, R.1
Agusti, C.2
Filella, X.3
-
31
-
-
0037314212
-
Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer
-
J.-L. Pujol, X. Quantin, W. Jacot, J.-M. Boher, J. Grenier, and P.-J. Lamy, "Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer, " Lung Cancer, vol. 39, no. 2, pp. 131-138, 2003.
-
(2003)
Lung Cancer
, vol.39
, Issue.2
, pp. 131-138
-
-
Pujol, J.-L.1
Quantin, X.2
Jacot, W.3
Boher, J.-M.4
Grenier, J.5
Lamy, P.-J.6
-
32
-
-
34250734403
-
Value of tumour and inflammatory markers in lung cancer
-
G. M. Oremek, H. Sauer-Eppel, and T. H. Bruzdziak, "Value of tumour and inflammatory markers in lung cancer, " Anticancer Research, vol. 27, pp. 1911-1915, 2007.
-
(2007)
Anticancer Research
, vol.27
, pp. 1911-1915
-
-
Oremek, G.M.1
Sauer-Eppel, H.2
Bruzdziak, T.H.3
-
33
-
-
75149119733
-
The diagnostic and prognostic value of ProGRP in lung cancer
-
B. Nisman, H. Biran, N. Ramu, N. Heching, V. Barak, and T. Peretz, "The diagnostic and prognostic value of ProGRP in lung cancer, " Anticancer Research, vol. 29, pp. 4827-4832, 2009.
-
(2009)
Anticancer Research
, vol.29
, pp. 4827-4832
-
-
Nisman, B.1
Biran, H.2
Ramu, N.3
Heching, N.4
Barak, V.5
Peretz, T.6
-
34
-
-
55749100686
-
ProGRP and NSE in therapy monitoring in patients with small cell lung cancer
-
E. Wójcik, J. K. Kulpa, B. Sas-Korczýnska, S. Korzeniowski, and J. Jakubowicz, "ProGRP and NSE in therapy monitoring in patients with small cell lung cancer, " Anticancer Research, vol. 28, pp. 3027-3033, 2008.
-
(2008)
Anticancer Research
, vol.28
, pp. 3027-3033
-
-
Wójcik, E.1
Kulpa, J.K.2
Sas-Korczýnska, B.3
Korzeniowski, S.4
Jakubowicz, J.5
-
35
-
-
0031041970
-
Serum levels of Pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer
-
T. Okusaka, K. Eguchi, and T. Kasai, "Serum levels of Pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer, " Clinical Cancer Research, vol. 3, pp. 123-127, 1997.
-
(1997)
Clinical Cancer Research
, vol.3
, pp. 123-127
-
-
Okusaka, T.1
Eguchi, K.2
Kasai, T.3
-
36
-
-
3042552039
-
Pro-gastrin-releasing peptide in patients with benign and malignant diseases
-
R. Molina, J. M. Auge, J. Alicarte, X. Filella, N. Viñolas, and A. M. Ballesta, "Pro-gastrin-releasing peptide in patients with benign and malignant diseases, " Tumor Biology, vol. 25, no. 1-2, pp. 56-61, 2004.
-
(2004)
Tumor Biology
, vol.25
, Issue.1-2
, pp. 56-61
-
-
Molina, R.1
Auge, J.M.2
Alicarte, J.3
Filella, X.4
Viñolas, N.5
Ballesta, A.M.6
-
37
-
-
79955630045
-
Plasma proGRP concentration is sensitive and specific for discriminating small cell lung cancer from nonmalignant conditions or non-small cell lung cancer
-
H.-R. Kim, I.-J. Oh, M.-G. Shin et al., "Plasma proGRP concentration is sensitive and specific for discriminating small cell lung cancer from nonmalignant conditions or non-small cell lung cancer, " Journal of Korean Medical Science, vol. 26, no. 5, pp. 625-630, 2011.
-
(2011)
Journal of Korean Medical Science
, vol.26
, Issue.5
, pp. 625-630
-
-
Kim, H.-R.1
Oh, I.-J.2
Shin, M.-G.3
-
38
-
-
84940100919
-
The 2015 World Health Organization classification of lung tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification
-
W. D. Travis, E. Brambilla, A. G. Nicholson et al., "The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification, " Journal ofThoracic Oncology, vol. 10, no. 9, pp. 1243-1260, 2015.
-
(2015)
Journal OfThoracic Oncology
, vol.10
, Issue.9
, pp. 1243-1260
-
-
Travis, W.D.1
Brambilla, E.2
Nicholson, A.G.3
-
39
-
-
85017325012
-
-
NCCN guidelines 2017, https://www.nccn. org/store/login/login. aspxreturnURL=https://www.nccn. org/professionals/physician- gls/pdf/sclc. pdf.
-
(2017)
NCCN Guidelines
-
-
|